RE: Guardian article1 Nov 2020 18:32
When news does get out there will be a stampede! I remember Avacta mid March around 26p a share. I bought a few and sold at average of 65p a few weeks later, put some more into Sareum as were just too good to miss.
Point here is Avacta became 'could hit 70p a share by year end), they have gone over 2 pounds a share. They do not have a treatment for Covid-19. Sareum have Tyk2 Jak1 inhibitor proven effective for Lupus and without the difficulties caused by Jak 2. Very targeted, very precise. A prime candidate for treatment of Covid-19 as endorsed by the grant.
Seriously, this share has had its ups and downs, but we are now so close to fruition. A great bunch on here including some of the newer posters. Thoth 2 has done well and kept the boat steady. 'When you can keep your ahead around you when all are loosing theirs' I think he should have been given one of the share options at 0.25p
Next news due on all fronts. Tyk2 1801, 1802, FLT3 (or flit 3 as Tim calls it) and SRA 737.
Regards to all!